FDA Approves Zepbound to Treat Obstructive Sleep Apnea

Photo of zepbound medicine

The U.S. Food and Drug Administration has authorized the use of  Eli Lilly & Co.’s Zepbound for adults with obesity and moderate to severe obstructive sleep apnea, a common condition where a person struggles to breathe properly during sleep.

FDA Expands Approval to wilate for Prophylaxis in All Types of VWDr

FDA Expands Approval to wilate for Prophylaxis in All Types of VWDr

Octapharma USA’s wilate, von Willebrand factor (VWF)/coagulation factor VIII complex (human) lyophilized power for solution for intravenous injection, has been given expanded approval by the U.S. Food and Drug Administration (FDA) for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children aged 6 and older with any type of von Willebrand disease (VWD).